Literature DB >> 24217308

Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.

G Hardy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24217308

Source DB:  PubMed          Journal:  Cardiovasc J Afr        ISSN： 1015-9657            Impact factor:   1.167


× No keyword cloud information.
  1 in total

1.  Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP-1-dependent nephrocyte apoptosis.

Authors:  Xiaowei Xing; Shuang Guo; Yusheng Liu; Jiangying Kuang; Zhiwei Huang; Xin Wang; Qinghua Lu
Journal:  Exp Ther Med       Date:  2021-07-14       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.